Business / Finance

RSS

Sorbent expands $36M Series B financing

Sorbent Therapeutics, a private biopharmaceutical company developing therapies for cardiovascular and renal disorders, announced today that it has expanded the Company's Series B financing from September 2010 by $36 million.

30 Jun 2011

AEGEA completes $13.3M private equity financing

AEGEA Medical Inc., developer of a novel, minimally invasive treatment for abnormal uterine bleeding, reported today that it has completed a $13.3 million private equity financing led by Covidien Ventures.

30 Jun 2011

Golden Meditech total turnover increases 15% to HK$328,066,000 for year ended 31 March, 2011

Golden Meditech Holdings Limited, a leading integrated healthcare enterprise in China, is pleased to announce the Group's annual results for the year ended 31 March, 2011.

30 Jun 2011

Cell Therapeutics to sell $30 million of Preferred Stock and warrants in registered offering

Cell Therapeutics, Inc. today announced that it has entered into an agreement to sell, subject to customary closing conditions, $30 million of shares of its Series 13 Preferred Stock and warrants to purchase shares of its common stock in a registered offering to six institutional investors.

30 Jun 2011

China Health first quarter gross revenues increase 52% to $6.759 million

China Health Labs & Diagnostics Ltd. is pleased to announce the financial results for the first quarter ended March 31, 2011.

29 Jun 2011

Exciton enters distribution agreement with Marathon Medical

Exciton Technologies Inc. today announced the Company has signed a distribution agreement with Marathon Medical, adding them to the existing Federal Supply Schedule (FSS) contract, administered by the Department of Veterans Affairs on behalf of the U.S. General Services Administration (GSA), effective July 1st.

29 Jun 2011

Cipher grants Vertical exclusive U.S. distribution rights to CIP-TRAMADOL ER

Cipher Pharmaceuticals Inc. today announced that it has entered into a definitive distribution and supply agreement with Vertical Pharmaceuticals, Inc., a U.S.-based specialty pharmaceutical company, under which Cipher has granted Vertical the exclusive right to market, sell and distribute CIP-TRAMADOL ER in the United States.

29 Jun 2011

Acetylon to advance ACY-1215 drug candidate with $27M Series B Preferred equity investment round of financing

Acetylon Pharmaceuticals, Inc. announced today that it has completed a $27 million Series B Preferred equity investment round of financing.

29 Jun 2011

RxMD and GlycoRegImmune enter drug development collaboration

RxMD, Inc., a privately-held, global therapeutics development company, today announced a collaboration agreement with GlycoRegImmune Inc. (GRI) to develop new treatments for inflammatory, autoimmune, and neurodegenerative conditions based on GRI's novel natural killer (NK) T cell targeted technologies.

29 Jun 2011

A.P. Pharma enters into definitive agreements for $24M private placement of common stock and warrants

A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that it has entered into definitive agreements with certain new and existing accredited investors providing for a private placement of common stock and warrants in which the Company will receive $24 million in gross proceeds.

29 Jun 2011

DiagnoCure, Signal Genetics enter commercialization collaboration for Previstage GCC Colorectal Cancer Staging Test

Signal Genetics, a privately held predictive genetic testing company focusing on oncology, and DiagnoCure, Inc., a life sciences company that develops and commercializes high-value cancer diagnostic tests, today announced a collaboration arrangement valued at US$13.3M over the first five years.

29 Jun 2011

Amorfix fiscal 2011 net loss decreases to $3,330,437

Amorfix Life Sciences, a product development company focused on diagnostics and therapeutics for misfolded protein diseases, today announced its operational and financial results for the year ended March 31, 2011, as well as financial results for the fourth quarter.

29 Jun 2011

Hi-Tech Pharmacal pays $3.6M for rights to Atley's branded pain treatment products

Hi-Tech Pharmacal Co., Inc., a specialty pharmaceuticals company, announced today that they acquired marketing and distribution rights to several unique branded products for the treatment of pain from Atley Pharmaceuticals. Some products are approved and some are pending approval with the Food and Drug Administration (FDA).

29 Jun 2011

Medivir, Meda renegotiate agreement for cold sores medicine, Xerese

Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, today announced that it has renegotiated the terms of its commercial partnership with Meda for Xerese, its unique marketed product for cold sores (herpes labialis).

29 Jun 2011

Aetna acquires Prodigy Health Group

Aetna today announced that it has completed its acquisition of Prodigy Health Group, the nation's largest independent third party administrator (TPA) of self-funded health care plans.

29 Jun 2011

U.Va. and Epsilon partner to provide commercial version of computer-based diabetes simulation tool

A computer-based diabetes simulation tool developed by University of Virginia researchers is now commercially available, thanks to a partnership with the Charlottesville-based medical research firm The Epsilon Group. The simulator is the only protocol that has been accepted by the U.S. Food and Drug Administration as an alternative to animal testing of Type 1 diabetes control strategies.

29 Jun 2011

bioMD changes name to Allied Healthcare Group

bioMD Limited (ASX: BOD) today announced a change of corporate name to reflect the merger with Allied Medical Ltd earlier this month. The new Company will be called Allied Healthcare Group Ltd and trade under the ASX code AHZ.

28 Jun 2011

GM Hospital Group acquires Beijing hospital facility for HK$600,000,000

Golden Meditech Holdings Limited, is pleased to announce the acquisition of a hospital facility in Beijing's Haidian District for a total consideration of HK$600,000,000.

28 Jun 2011

Tibotec, Gilead Sciences enter license agreement for new combination product of PREZISTA and cobicistat

Tibotec Pharmaceuticals today announced that it has entered into a license agreement with Gilead Sciences, Inc., for the development and commercialization of a new once-daily single tablet fixed-dose antiretroviral combination product containing Tibotec's protease inhibitor PREZISTA® (darunavir) and Gilead's cobicistat, an investigational pharmacoenhancing or "boosting" agent.

28 Jun 2011

Nimbus Discovery closes $24 million Series A financing

Nimbus Discovery LLC, a biopharmaceutical company using state-of-the-art computational technology to discover novel medicines against exciting but previously inaccessible disease targets, today announced the close of a $24M Series A financing.

28 Jun 2011

Business / Finance

Sorbent expands $36M Series B financing

AEGEA completes $13.3M private equity financing

Golden Meditech total turnover increases 15% to HK$328,066,000 for year ended 31 March, 2011

Cell Therapeutics to sell $30 million of Preferred Stock and warrants in registered offering

China Health first quarter gross revenues increase 52% to $6.759 million

Exciton enters distribution agreement with Marathon Medical

Cipher grants Vertical exclusive U.S. distribution rights to CIP-TRAMADOL ER

Acetylon to advance ACY-1215 drug candidate with $27M Series B Preferred equity investment round of financing

RxMD and GlycoRegImmune enter drug development collaboration

A.P. Pharma enters into definitive agreements for $24M private placement of common stock and warrants

DiagnoCure, Signal Genetics enter commercialization collaboration for Previstage GCC Colorectal Cancer Staging Test

Amorfix fiscal 2011 net loss decreases to $3,330,437

Hi-Tech Pharmacal pays $3.6M for rights to Atley's branded pain treatment products

Medivir, Meda renegotiate agreement for cold sores medicine, Xerese

Aetna acquires Prodigy Health Group

U.Va. and Epsilon partner to provide commercial version of computer-based diabetes simulation tool

bioMD changes name to Allied Healthcare Group

GM Hospital Group acquires Beijing hospital facility for HK$600,000,000

Tibotec, Gilead Sciences enter license agreement for new combination product of PREZISTA and cobicistat

Nimbus Discovery closes $24 million Series A financing

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Latest News